For 48 years of establishment and development (November 28th, 1972 - November 28th, 2020), Traphaco Joint Stock Company has continuously been the leading pharmaceutical brand in the country, honored at prestigious awards.

Traphaco's 4.0 smart pharmaceutical factory

By the end of 2020, Traphaco won the "Typical Enterprise for Laborers 2019 - 2020" award and the Prime Minister's Certificate of Merit; National Brand (Vietnam Value) 2020 for the 5th time in a row; Honored to be a Vietnam Sustainable Enterprise (CSI) 2020 ...

Regarding the sustainable achievements of Traphaco during the past 48 years, Trapaco's General Director, Mr. Tran Tuc Ma affirmed: `` The continuous efforts of all generations of employees throughout the company in maintaining the spirit of enthusiastic in production, has built and maintained the position of the leading brand in the pharmaceutical industry in Vietnam ''.

''Traphaco is representing for a very small number of businesses that make a difference in value when building the Traphaco Culture Ministry, based on precise evaluation indicators, '' said the leading experts in pharmaceuticals. This is to affirm the unique corporate culture of the company, enhance the sense of responsibility and sense of work of the staff in the whole system, and demonstrate the human bravery of Traphaco ''.

Proactively implement with confidence

''Unexpected changes have made businesses, including Traphaco, face difficult challenges in 2020. But we understand and must be flexible and confident to have appropriate responses'', Mr. Tran Tuc Ma said.

As soon as the Covid-19 epidemic broke out, the company actively negotiated with suppliers to ensure uninterrupted supply of raw materials; quickly set up an online consulting group, increasing customer contact activities through online channels. These flexible and synchronous measures helped Traphaco achieve good growth in the first quarter, both in revenue and profit.

In the second quarter of 2020, the company proactively applied customer personalization, designed a flexible sales policy, creating mutual benefits between customers and the company. Thereby, maintaining revenue and profit growth through the second quarter was full of difficulties and challenges.

In the third quarter of 2020, the company continued to apply a flexible sales policy, focusing on promoting key products, continued to grow 22% in revenue and 46% in profit.

``In 2020, we grow 12% in revenue and 27% in profit after tax compared to the same period in 2019. This is a good growth compared to pharmaceutical companies listed on the stock market '', Mr. Tran Tuc Ma and the Traphaco team announced.

Traphaco's General Director - Mr. Tran Tuc Ma visited the Quality Control Area at the factory

Oriental medicine was at the top, generic drugs made a breakthrough

For 48 years of construction and development, all over the country, Traphaco has affirmed its leading position in oriental medicine, pioneered in the development of high-quality pharmaceuticals, is a pioneer in implementing the sustainable pharmaceutical materials development model, is the first enterprise to have 6 growing areas meeting GACP-WHO standards for 6 medicinal herbs (polyscias fruticosa, ginkgo biloba, artichoke, Pharbitis nil, Ampelopsis cantoniensis).

According to the General Director of Traphaco, in the sustainable development strategy for the period 2017-2020, Traphaco leads the trend of Pharma 4.0, applying modern technology in production and distribution activities. "Smart" Pharmaceutical Factory in Hung Yen with synchronous investment, complete robotization and automation for production lines, has produced a series of products that are trusted by the market right from the very first finished product batches. This "smart" factory has steadily increased capacity since it officially went into production (in 2017).

''Traphaco will continue to exploit the efficiency of smart manufacturing technology through technology transfer and exclusive import of products from major pharmaceutical corporations in the world, expanding the portfolio of high strength products with high technology, optimal quality products are always brought to the market, '' asserted by Mr. Tran Tuc Ma.

Promoting the development of generic drug is expected to help Traphaco continue to maintain the prospect of positive revenue and profit growth, especially when the smart factory completes the investment process, upgrade to EU-GMP standard and can participate in bidding packages of groups 1 and 2 in ETC channel with better revenue and profit margin.